Catherine Ramsey
Stock Analyst at Baird
(4.58)
# 255
Out of 4,711 analysts
39
Total ratings
65.52%
Success rate
19.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Ramsey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Outperform | $46 → $48 | $47.94 | +0.13% | 5 | Nov 19, 2024 | |
| NTRA Natera | Maintains: Outperform | $120 → $160 | $161.88 | -1.16% | 5 | Nov 13, 2024 | |
| ILMN Illumina | Maintains: Neutral | $124 → $139 | $136.02 | +2.19% | 4 | Nov 6, 2024 | |
| RVTY Revvity | Maintains: Outperform | $136 → $138 | $112.56 | +22.60% | 3 | Nov 5, 2024 | |
| CSTL Castle Biosciences | Maintains: Outperform | $37 → $39 | $27.53 | +41.66% | 7 | Nov 5, 2024 | |
| WAT Waters | Maintains: Neutral | $319 → $312 | $368.16 | -15.25% | 7 | May 8, 2024 | |
| TMO Thermo Fisher | Maintains: Outperform | $695 → $665 | $524.05 | +26.90% | 2 | Nov 1, 2022 | |
| A Agilent Technologies | Maintains: Outperform | $155 → $160 | $134.51 | +18.95% | 5 | Aug 17, 2022 | |
| EXAS Exact Sciences | Maintains: Outperform | $90 → $75 | $59.40 | +26.26% | 1 | Aug 3, 2022 |
Twist Bioscience
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $48
Current: $47.94
Upside: +0.13%
Natera
Nov 13, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $161.88
Upside: -1.16%
Illumina
Nov 6, 2024
Maintains: Neutral
Price Target: $124 → $139
Current: $136.02
Upside: +2.19%
Revvity
Nov 5, 2024
Maintains: Outperform
Price Target: $136 → $138
Current: $112.56
Upside: +22.60%
Castle Biosciences
Nov 5, 2024
Maintains: Outperform
Price Target: $37 → $39
Current: $27.53
Upside: +41.66%
Waters
May 8, 2024
Maintains: Neutral
Price Target: $319 → $312
Current: $368.16
Upside: -15.25%
Thermo Fisher
Nov 1, 2022
Maintains: Outperform
Price Target: $695 → $665
Current: $524.05
Upside: +26.90%
Agilent Technologies
Aug 17, 2022
Maintains: Outperform
Price Target: $155 → $160
Current: $134.51
Upside: +18.95%
Exact Sciences
Aug 3, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $59.40
Upside: +26.26%